Werewolf Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
HOWL$1.010.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
1z
Consolidated Statements of Operations
(amounts in thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue: | ||
| Collaboration revenue | $— | $1,885 |
| Operating expenses: | ||
| Research and development | 44,830 | 56,434 |
| General and administrative | 15,847 | 19,045 |
| Total operating expenses | 60,677 | 75,479 |
| Operating loss | (60,677) | (73,594) |
| Other (expense) income: | ||
| Interest income | 3,108 | 6,673 |
| Interest expense | (5,274) | (4,656) |
| Loss on extinguishment of debt | — | (553) |
| Other income, net | 2,021 | 1,615 |
| Total other (expense) income | (145) | 3,079 |
| Net loss | $(60,822) | $(70,515) |
| Net loss per common share, basic | $(1.32) | $(1.63) |
| Net loss per common share, diluted | $(1.33) | $(1.63) |
| Weighted-average common shares outstanding, basic | 46,018,888 | 43,332,088 |
| Weighted-average common shares outstanding, diluted | 46,810,252 | 43,859,664 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.